246 related articles for article (PubMed ID: 30505937)
1. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
[TBL] [Abstract][Full Text] [Related]
2. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Currier MA; Eshun FK; Sholl A; Chernoguz A; Crawford K; Divanovic S; Boon L; Goins WF; Frischer JS; Collins MH; Leddon JL; Baird WH; Haseley A; Streby KA; Wang PY; Hendrickson BW; Brekken RA; Kaur B; Hildeman D; Cripe TP
Mol Ther; 2013 May; 21(5):1014-23. PubMed ID: 23481323
[TBL] [Abstract][Full Text] [Related]
3. Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.
Klose C; Berchtold S; Schmidt M; Beil J; Smirnow I; Venturelli S; Burkard M; Handgretinger R; Lauer UM
BMC Cancer; 2019 Dec; 19(1):1172. PubMed ID: 31795974
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
5. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.
Ringwalt EM; Currier MA; Glaspell AM; Chen CY; Cannon MV; Cam M; Gross AC; Gust M; Wang PY; Boon L; Biederman LE; Schwarz E; Rajappa P; Lee DA; Mardis ER; Carson WE; Roberts RD; Cripe TP
bioRxiv; 2024 Mar; ():. PubMed ID: 38464161
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma.
Jain K; Henrich IC; Quick L; Young R; Mondal S; Oliveira AM; Blobel GA; Chou MM
Cancer Res Commun; 2023 Aug; 3(8):1615-1627. PubMed ID: 37615015
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.
Studebaker AW; Hutzen BJ; Pierson CR; Haworth KB; Cripe TP; Jackson EM; Leonard JR
Mol Ther Oncolytics; 2017 Sep; 6():22-30. PubMed ID: 28649600
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
11. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
Denton NL; Chen CY; Scott TR; Cripe TP
Biomedicines; 2016 Jul; 4(3):. PubMed ID: 28536380
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
14. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
Currier MA; Sprague L; Rizvi TA; Nartker B; Chen CY; Wang PY; Hutzen BJ; Franczek MR; Patel AV; Chaney KE; Streby KA; Ecsedy JA; Conner J; Ratner N; Cripe TP
Oncotarget; 2017 Mar; 8(11):17412-17427. PubMed ID: 28147331
[TBL] [Abstract][Full Text] [Related]
15. Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.
Ring EK; Li R; Moore BP; Nan L; Kelly VM; Han X; Beierle EA; Markert JM; Leavenworth JW; Gillespie GY; Friedman GK
Mol Ther Oncolytics; 2017 Dec; 7():27-36. PubMed ID: 29034313
[TBL] [Abstract][Full Text] [Related]
16. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.
Zhang W; Hu X; Liang J; Zhu Y; Zeng B; Feng L; Zhao C; Liu S; Liu B; Zhang K
Mol Ther Oncolytics; 2020 Mar; 16():158-171. PubMed ID: 32055679
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.
Leddon JL; Chen CY; Currier MA; Wang PY; Jung FA; Denton NL; Cripe KM; Haworth KB; Arnold MA; Gross AC; Eubank TD; Goins WF; Glorioso JC; Cohen JB; Grandi P; Hildeman DA; Cripe TP
Mol Ther Oncolytics; 2015; 1():14010. PubMed ID: 27119100
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.
Currier MA; Gillespie RA; Sawtell NM; Mahller YY; Stroup G; Collins MH; Kambara H; Chiocca EA; Cripe TP
Mol Ther; 2008 May; 16(5):879-85. PubMed ID: 18388918
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.
Yin J; Markert JM; Leavenworth JW
Front Oncol; 2017; 7():136. PubMed ID: 28695111
[TBL] [Abstract][Full Text] [Related]
20. TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.
Hutzen B; Chen CY; Wang PY; Sprague L; Swain HM; Love J; Conner J; Boon L; Cripe TP
Mol Ther Oncolytics; 2017 Dec; 7():17-26. PubMed ID: 29034312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
